IONS vs. UTHR, INCY, BMRN, NBIX, EXEL, EXAS, RGEN, HALO, MDGL, and ALKS
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry.
Ionis Pharmaceuticals vs.
Ionis Pharmaceuticals (NASDAQ:IONS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
Ionis Pharmaceuticals presently has a consensus target price of $60.00, suggesting a potential upside of 84.05%. United Therapeutics has a consensus target price of $388.25, suggesting a potential upside of 25.23%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.
Ionis Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
In the previous week, United Therapeutics had 40 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 53 mentions for United Therapeutics and 13 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 1.04 beat Ionis Pharmaceuticals' score of 0.76 indicating that United Therapeutics is being referred to more favorably in the news media.
United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a net margin of 40.31% compared to Ionis Pharmaceuticals' net margin of -64.25%. United Therapeutics' return on equity of 19.22% beat Ionis Pharmaceuticals' return on equity.
93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 11.9% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Ionis Pharmaceuticals received 102 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 62.58% of users gave United Therapeutics an outperform vote while only 60.36% of users gave Ionis Pharmaceuticals an outperform vote.
Summary
United Therapeutics beats Ionis Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ionis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:IONS) was last updated on 3/4/2025 by MarketBeat.com Staff
